PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33914237-1 2021 Phosphodiesterase-10A (PDE10A) hydrolyse the secondary messengers cGMP and cAMP, two molecules playing important roles in neurodevelopment and brain functions. Cyclic AMP 75-79 phosphodiesterase 10A Homo sapiens 0-21 33914237-1 2021 Phosphodiesterase-10A (PDE10A) hydrolyse the secondary messengers cGMP and cAMP, two molecules playing important roles in neurodevelopment and brain functions. Cyclic AMP 75-79 phosphodiesterase 10A Homo sapiens 23-29 33914237-10 2021 In summary, these data indicate that PDE10A is involved in QUIN-mediated synaptotoxicity and its inhibition elicit neuroprotection by reducing the oxidative stress and protecting synaptic proteins via up-regulation of cAMP signalling cascade. Cyclic AMP 218-222 phosphodiesterase 10A Homo sapiens 37-43 33581555-1 2021 Phosphodiesterase 10A is a member of Phosphodiesterase (PDE)-superfamily of the enzyme which is responsible for hydrolysis of cAMP and cGMP to their inactive forms 5"-AMP and 5"-GMP, respectively. Cyclic AMP 126-130 phosphodiesterase 10A Homo sapiens 0-21 33581555-1 2021 Phosphodiesterase 10A is a member of Phosphodiesterase (PDE)-superfamily of the enzyme which is responsible for hydrolysis of cAMP and cGMP to their inactive forms 5"-AMP and 5"-GMP, respectively. Cyclic AMP 126-130 phosphodiesterase 10A Homo sapiens 0-17 33581555-1 2021 Phosphodiesterase 10A is a member of Phosphodiesterase (PDE)-superfamily of the enzyme which is responsible for hydrolysis of cAMP and cGMP to their inactive forms 5"-AMP and 5"-GMP, respectively. Cyclic AMP 126-130 phosphodiesterase 10A Homo sapiens 56-59 33658076-2 2021 Interestingly, two key modulators that elevate cAMP, the A2A receptor (A2AR) and phosphodiesterase 10A (PDE10A), are differentially co-expressed in various types of non-small lung cancer (NSCLC) cell-lines. Cyclic AMP 47-51 phosphodiesterase 10A Homo sapiens 81-102 33658076-2 2021 Interestingly, two key modulators that elevate cAMP, the A2A receptor (A2AR) and phosphodiesterase 10A (PDE10A), are differentially co-expressed in various types of non-small lung cancer (NSCLC) cell-lines. Cyclic AMP 47-51 phosphodiesterase 10A Homo sapiens 104-110 31801360-12 2020 TP-10 treatment elevated both cAMP and cGMP levels in cardiac myocytes and cardiac fibroblasts, consistent with PDE10A as a cAMP/cGMP dual-specific PDE. Cyclic AMP 124-128 phosphodiesterase 10A Homo sapiens 112-118 33551724-1 2020 PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. Cyclic AMP 50-54 phosphodiesterase 10A Homo sapiens 0-6 33551724-1 2020 PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. Cyclic AMP 50-54 phosphodiesterase 10A Homo sapiens 10-27 31119377-2 2020 PDE10A acts postsynaptically on striatal dopamine signaling by regulating neuronal excitability through its inhibition of cyclic adenosine monophosphate (cAMP), and we recently found it to be reduced in schizophrenia compared to controls. Cyclic AMP 122-152 phosphodiesterase 10A Homo sapiens 0-6 31119377-2 2020 PDE10A acts postsynaptically on striatal dopamine signaling by regulating neuronal excitability through its inhibition of cyclic adenosine monophosphate (cAMP), and we recently found it to be reduced in schizophrenia compared to controls. Cyclic AMP 154-158 phosphodiesterase 10A Homo sapiens 0-6 31874060-1 2020 Introduction: Phosphodiesterase 10 (PDE10) is one of at least 11 different PDE families, which are the enzymes that degrade adenosine 3",5"-cyclic monophosphate (cAMP) and/or guanosine 3",5"-cyclic monophosphate (cGMP) by hydrolyzing the phosphodiester bonds. Cyclic AMP 124-160 phosphodiesterase 10A Homo sapiens 36-39 31874060-1 2020 Introduction: Phosphodiesterase 10 (PDE10) is one of at least 11 different PDE families, which are the enzymes that degrade adenosine 3",5"-cyclic monophosphate (cAMP) and/or guanosine 3",5"-cyclic monophosphate (cGMP) by hydrolyzing the phosphodiester bonds. Cyclic AMP 162-166 phosphodiesterase 10A Homo sapiens 36-39 31874060-2 2020 Inhibition of PDE10A represents a molecular target in the treatment of conditions that would benefit from the increase of the level of cAMP and/or cGMP such as neurological and psychiatric disorders, cancer, and diabetes.Areas covered: The present article reviews the patent literature on PDE10A inhibitors (PDE10AIs) from 2014 to present and PDE10AI chemotypes from different chemical classes: heteroaryl- and aryl-nitrogen-heterocyclic compounds, unsaturated nitrogen-heterocyclic compounds with specific substituents such as pyrazolopyrimidine, aryloxymethyl cyclopropane, pyridizinone, imidazopyridine, triazoles and imidazo[2,1-a]isoidole. Cyclic AMP 135-139 phosphodiesterase 10A Homo sapiens 14-20 31874060-2 2020 Inhibition of PDE10A represents a molecular target in the treatment of conditions that would benefit from the increase of the level of cAMP and/or cGMP such as neurological and psychiatric disorders, cancer, and diabetes.Areas covered: The present article reviews the patent literature on PDE10A inhibitors (PDE10AIs) from 2014 to present and PDE10AI chemotypes from different chemical classes: heteroaryl- and aryl-nitrogen-heterocyclic compounds, unsaturated nitrogen-heterocyclic compounds with specific substituents such as pyrazolopyrimidine, aryloxymethyl cyclopropane, pyridizinone, imidazopyridine, triazoles and imidazo[2,1-a]isoidole. Cyclic AMP 135-139 phosphodiesterase 10A Homo sapiens 289-295 31801360-12 2020 TP-10 treatment elevated both cAMP and cGMP levels in cardiac myocytes and cardiac fibroblasts, consistent with PDE10A as a cAMP/cGMP dual-specific PDE. Cyclic AMP 124-128 phosphodiesterase 10A Homo sapiens 112-115 30951862-1 2019 The dual-specific cAMP/cGMP phosphodiesterase PDE10A is exclusively localised to regions of the brain and specific cell types that control crucial brain circuits and behaviours. Cyclic AMP 18-22 phosphodiesterase 10A Homo sapiens 46-52 31404565-1 2019 Phosphodiesterase 10A (PDE10A) is a dual-substrate PDE that hydrolyzes both cAMP and cGMP. Cyclic AMP 76-80 phosphodiesterase 10A Homo sapiens 23-26 30091414-2 2019 Phosphodiesterase 10A (PDE10A) is a double substrate enzyme that hydrolyzes second messenger molecules such as cyclic-3",5"-adenosine monophosphate (cAMP) and cyclic-3",5"-guanosine monophosphate (cGMP). Cyclic AMP 149-153 phosphodiesterase 10A Homo sapiens 0-21 30091414-2 2019 Phosphodiesterase 10A (PDE10A) is a double substrate enzyme that hydrolyzes second messenger molecules such as cyclic-3",5"-adenosine monophosphate (cAMP) and cyclic-3",5"-guanosine monophosphate (cGMP). Cyclic AMP 149-153 phosphodiesterase 10A Homo sapiens 23-29 30345538-1 2018 BACKGROUND: Striatal cyclic adenosine monophosphate activity modulates movement and is determined from the balance between its synthesis by adenylate cyclase 5 (ADCY5) and its degradation by phosphodiesterase 10A (PDE10A). Cyclic AMP 21-51 phosphodiesterase 10A Homo sapiens 191-212 30345538-1 2018 BACKGROUND: Striatal cyclic adenosine monophosphate activity modulates movement and is determined from the balance between its synthesis by adenylate cyclase 5 (ADCY5) and its degradation by phosphodiesterase 10A (PDE10A). Cyclic AMP 21-51 phosphodiesterase 10A Homo sapiens 214-220 29223715-1 2018 INTRODUCTION: Phosphodiesterase 10A (PDE10A) is a member of the PDE enzyme family that degrades cyclic adenosine and guanosine monophosphates (cAMP and cGMP). Cyclic AMP 143-147 phosphodiesterase 10A Homo sapiens 14-35 29508924-2 2018 Phosphodiesterase 10A regulates cyclic adenosine monophosphate and cyclic guanosine monophosphate, which mediate responses to dopamine receptor activation, and the levels of these cyclic nucleotides are decreased in experimental models of l-dopa-induced dyskinesia. Cyclic AMP 32-62 phosphodiesterase 10A Homo sapiens 0-21 29508924-3 2018 The elevation of cyclic adenosine monophosphate/cyclic guanosine monophosphate levels by phosphodiesterase 10A inhibition may thus be targeted to reduce l-dopa-induced dyskinesia. Cyclic AMP 17-47 phosphodiesterase 10A Homo sapiens 89-110 29223715-1 2018 INTRODUCTION: Phosphodiesterase 10A (PDE10A) is a member of the PDE enzyme family that degrades cyclic adenosine and guanosine monophosphates (cAMP and cGMP). Cyclic AMP 143-147 phosphodiesterase 10A Homo sapiens 37-43 29223715-1 2018 INTRODUCTION: Phosphodiesterase 10A (PDE10A) is a member of the PDE enzyme family that degrades cyclic adenosine and guanosine monophosphates (cAMP and cGMP). Cyclic AMP 143-147 phosphodiesterase 10A Homo sapiens 37-40 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 86-116 phosphodiesterase 10A Homo sapiens 0-21 29130591-1 2018 PDE10A encodes a dual cAMP-cGMP phosphodiesterase that is enriched in the medium spiny neurons of the corpus striatum in the brain and plays an important role in basal ganglia circuitry. Cyclic AMP 22-26 phosphodiesterase 10A Homo sapiens 0-6 29290010-2 2017 In particular, suitable compounds may be useful in treating neurodegenerative diseases by promoting neuronal survival in a synergistic manner via their multi-target activity at the adenosine A1 and A2A receptors (A1R and A2AR) and phosphodiesterase 10A (PDE10A), which modulate intracellular cAMP levels. Cyclic AMP 292-296 phosphodiesterase 10A Homo sapiens 254-260 28462841-1 2017 Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. Cyclic AMP 111-115 phosphodiesterase 10A Homo sapiens 0-18 28569061-1 2017 Phosphodiesterases (PDE) hydrolyze both cyclic AMP and GMP (cAMP/cGMP) and are responsible for the regulation of their levels in a multitude of cellular functions. Cyclic AMP 60-64 phosphodiesterase 10A Homo sapiens 0-18 28569061-1 2017 Phosphodiesterases (PDE) hydrolyze both cyclic AMP and GMP (cAMP/cGMP) and are responsible for the regulation of their levels in a multitude of cellular functions. Cyclic AMP 60-64 phosphodiesterase 10A Homo sapiens 20-23 28569061-6 2017 All four ligands bind the PDE10A cAMP binding domain with affinity in the micromolar range. Cyclic AMP 33-37 phosphodiesterase 10A Homo sapiens 26-32 27539962-2 2016 Phosphodiesterase 10A (PDE10A) inhibitors have been considered as therapeutic agents for schizophrenia because the regulation of cAMP and cGMP in the striatum by PDE10A plays an important role in the signaling mechanisms of the striatal-cortical network, and thereby in cognitive function. Cyclic AMP 129-133 phosphodiesterase 10A Homo sapiens 0-21 27539962-2 2016 Phosphodiesterase 10A (PDE10A) inhibitors have been considered as therapeutic agents for schizophrenia because the regulation of cAMP and cGMP in the striatum by PDE10A plays an important role in the signaling mechanisms of the striatal-cortical network, and thereby in cognitive function. Cyclic AMP 129-133 phosphodiesterase 10A Homo sapiens 23-29 27539962-2 2016 Phosphodiesterase 10A (PDE10A) inhibitors have been considered as therapeutic agents for schizophrenia because the regulation of cAMP and cGMP in the striatum by PDE10A plays an important role in the signaling mechanisms of the striatal-cortical network, and thereby in cognitive function. Cyclic AMP 129-133 phosphodiesterase 10A Homo sapiens 162-168 26095589-5 2015 As an integral component in the regulation of the second messengers cyclic AMP and cyclic GMP, and thus their cognate signaling pathways, PDEs present intriguing targets for pharmacotherapies to combat alcohol use disorders. Cyclic AMP 68-78 phosphodiesterase 10A Homo sapiens 138-142 26095589-6 2015 As activation of cAMP/cGMP-dependent signaling cascades can dampen alcohol intake, PDE inhibitors may provide a novel target for reducing excessive alcohol consumption, as has been proposed for PDE4 and PDE10A. Cyclic AMP 17-21 phosphodiesterase 10A Homo sapiens 83-86 26095589-6 2015 As activation of cAMP/cGMP-dependent signaling cascades can dampen alcohol intake, PDE inhibitors may provide a novel target for reducing excessive alcohol consumption, as has been proposed for PDE4 and PDE10A. Cyclic AMP 17-21 phosphodiesterase 10A Homo sapiens 203-209 28439226-1 2017 Phosphodiesterase regulates the homeostasis of cAMP and cGMP, which increase the strength of excitatory neural circuits and/or decrease inhibitory synaptic plasticity. Cyclic AMP 47-51 phosphodiesterase 10A Homo sapiens 0-17 27058447-4 2016 PDE10A contributes to the regulation of the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 68-98 phosphodiesterase 10A Homo sapiens 0-6 27058447-4 2016 PDE10A contributes to the regulation of the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 100-104 phosphodiesterase 10A Homo sapiens 0-6 27058447-5 2016 Both substitutions affect highly conserved amino acids located in the regulatory GAF-B domain, which, by binding to cAMP, stimulates the activity of the PDE10A catalytic domain. Cyclic AMP 116-120 phosphodiesterase 10A Homo sapiens 153-159 27058447-8 2016 The identification of PDE10A mutations as a cause of chorea further motivates the study of cAMP signaling in MSNs and highlights the crucial role of striatal cAMP signaling in the regulation of basal ganglia circuitry. Cyclic AMP 91-95 phosphodiesterase 10A Homo sapiens 22-28 27058447-8 2016 The identification of PDE10A mutations as a cause of chorea further motivates the study of cAMP signaling in MSNs and highlights the crucial role of striatal cAMP signaling in the regulation of basal ganglia circuitry. Cyclic AMP 158-162 phosphodiesterase 10A Homo sapiens 22-28 26713600-1 2016 Phosphodiesterase 10A (PDE10) is a cGMP and cAMP degrading PDE isozyme that is highly expressed in the brain striatum where it appears to play an important role in cognition and psychomotor activity. Cyclic AMP 44-48 phosphodiesterase 10A Homo sapiens 0-21 26713600-1 2016 Phosphodiesterase 10A (PDE10) is a cGMP and cAMP degrading PDE isozyme that is highly expressed in the brain striatum where it appears to play an important role in cognition and psychomotor activity. Cyclic AMP 44-48 phosphodiesterase 10A Homo sapiens 23-28 26713600-1 2016 Phosphodiesterase 10A (PDE10) is a cGMP and cAMP degrading PDE isozyme that is highly expressed in the brain striatum where it appears to play an important role in cognition and psychomotor activity. Cyclic AMP 44-48 phosphodiesterase 10A Homo sapiens 23-26 26713600-5 2016 Here we report that the concentration range by which the highly specific PDE10 inhibitor, Pf-2545920 (MP-10), inhibits colon tumor cell growth parallels the concentration range required to increase cGMP and cAMP levels, and activates PKG and PKA, respectively. Cyclic AMP 207-211 phosphodiesterase 10A Homo sapiens 73-78 26198591-3 2015 PDE10A hydrolyses cAMP/cGMP signalling cascades, thus having a key role in the regulation of striatal output, and in promoting neuronal survival. Cyclic AMP 18-22 phosphodiesterase 10A Homo sapiens 0-6 26210536-2 2015 Phosphodiesterase 10A (PDE10A) is a basal ganglia expressed dual substrate enzyme, which regulates cAMP and cGMP signalling cascades, thus having a key role in the regulation of dopaminergic signalling in striatal pathways, and in promoting neuronal survival. Cyclic AMP 99-103 phosphodiesterase 10A Homo sapiens 0-21 26210536-2 2015 Phosphodiesterase 10A (PDE10A) is a basal ganglia expressed dual substrate enzyme, which regulates cAMP and cGMP signalling cascades, thus having a key role in the regulation of dopaminergic signalling in striatal pathways, and in promoting neuronal survival. Cyclic AMP 99-103 phosphodiesterase 10A Homo sapiens 23-29 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 86-116 phosphodiesterase 10A Homo sapiens 23-29 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 86-116 phosphodiesterase 10A Homo sapiens 23-26 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 118-122 phosphodiesterase 10A Homo sapiens 0-21 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 118-122 phosphodiesterase 10A Homo sapiens 23-29 25891816-1 2015 Phosphodiesterase 10A (PDE10A) is a member of the PDE family of enzymes that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Cyclic AMP 118-122 phosphodiesterase 10A Homo sapiens 23-26 23160998-1 2013 PURPOSE: Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP-hydrolysing enzyme with a central role in striatal signalling and implicated in neuropsychiatric disorders such as Huntington"s disease, Parkinson"s disease, schizophrenia and addiction. Cyclic AMP 45-49 phosphodiesterase 10A Homo sapiens 9-30 25159072-5 2015 We will review the localization of PDE10A, both within the brain and the neuron and discuss how its role in regulating cAMP and cGMP accumulation modulates intracellular signaling pathways. Cyclic AMP 119-123 phosphodiesterase 10A Homo sapiens 35-41 25295858-1 2014 Phosphodiesterases (PDEs) regulate the levels of the second messengers cAMP and cGMP and are important drug targets. Cyclic AMP 71-75 phosphodiesterase 10A Homo sapiens 0-18 25295858-1 2014 Phosphodiesterases (PDEs) regulate the levels of the second messengers cAMP and cGMP and are important drug targets. Cyclic AMP 71-75 phosphodiesterase 10A Homo sapiens 20-24 25297556-5 2014 A potential therapeutic target in the management of T2DM lies in regulating the activity of phosphodiesterases (PDEs), which degrade cAMP. Cyclic AMP 133-137 phosphodiesterase 10A Homo sapiens 92-110 25297556-5 2014 A potential therapeutic target in the management of T2DM lies in regulating the activity of phosphodiesterases (PDEs), which degrade cAMP. Cyclic AMP 133-137 phosphodiesterase 10A Homo sapiens 112-116 24898025-1 2014 UNLABELLED: Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed in medium-sized spiny neurons of the striatum, making it an attractive target for novel therapies for a variety of neurologic and psychiatric disorders that involve striatal function. Cyclic AMP 83-113 phosphodiesterase 10A Homo sapiens 31-39 23691025-5 2013 Of interest, we found increased expression of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA restored cAMP/PKA signaling. Cyclic AMP 172-176 phosphodiesterase 10A Homo sapiens 46-67 23691025-5 2013 Of interest, we found increased expression of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA restored cAMP/PKA signaling. Cyclic AMP 172-176 phosphodiesterase 10A Homo sapiens 69-75 23691025-5 2013 Of interest, we found increased expression of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA restored cAMP/PKA signaling. Cyclic AMP 172-176 phosphodiesterase 10A Homo sapiens 150-156 23691025-7 2013 In conclusion, our data show that HPRT-deficiency alters cAMP/PKA signaling pathway, which is in part due to the increased of PDE10A expression and activity. Cyclic AMP 57-61 phosphodiesterase 10A Homo sapiens 126-132 23354020-1 2013 As a potential target for the treatment of schizophrenia, the dual cAMP/cGMP hydrolyzing enzyme PDE10A has attracted a significant amount of attention. Cyclic AMP 67-71 phosphodiesterase 10A Homo sapiens 96-102 23160998-1 2013 PURPOSE: Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP-hydrolysing enzyme with a central role in striatal signalling and implicated in neuropsychiatric disorders such as Huntington"s disease, Parkinson"s disease, schizophrenia and addiction. Cyclic AMP 45-49 phosphodiesterase 10A Homo sapiens 32-38 21886636-4 2011 RESULTS: PDEs selective for cAMP (PDE4A, PDE4D, and PDE8A) and cGMP (PDE9A) as well a dual specificity PDE (PDE10A) were detected in the sensory epithelium of the saccule. Cyclic AMP 28-32 phosphodiesterase 10A Homo sapiens 9-12 21886636-4 2011 RESULTS: PDEs selective for cAMP (PDE4A, PDE4D, and PDE8A) and cGMP (PDE9A) as well a dual specificity PDE (PDE10A) were detected in the sensory epithelium of the saccule. Cyclic AMP 28-32 phosphodiesterase 10A Homo sapiens 108-114 21695637-1 2011 Cyclic nucleotide phosphodiesterases (PDEs) share a highly conserved catalytic domain that hydrolyzes cAMP, cGMP, or both nucleotides. Cyclic AMP 102-106 phosphodiesterase 10A Homo sapiens 38-42 21695637-5 2011 In addition, the structures of PDE10A in complex with cAMP and cGMP reveal that cAMP and cGMP bind to the active site in different orientations and have different interactions with PDE10A residues. Cyclic AMP 54-58 phosphodiesterase 10A Homo sapiens 31-37 21695637-5 2011 In addition, the structures of PDE10A in complex with cAMP and cGMP reveal that cAMP and cGMP bind to the active site in different orientations and have different interactions with PDE10A residues. Cyclic AMP 54-58 phosphodiesterase 10A Homo sapiens 181-187 21695637-5 2011 In addition, the structures of PDE10A in complex with cAMP and cGMP reveal that cAMP and cGMP bind to the active site in different orientations and have different interactions with PDE10A residues. Cyclic AMP 80-84 phosphodiesterase 10A Homo sapiens 31-37 21695637-5 2011 In addition, the structures of PDE10A in complex with cAMP and cGMP reveal that cAMP and cGMP bind to the active site in different orientations and have different interactions with PDE10A residues. Cyclic AMP 80-84 phosphodiesterase 10A Homo sapiens 181-187 21931705-0 2011 Cyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localization. Cyclic AMP 0-10 phosphodiesterase 10A Homo sapiens 65-82 21931705-2 2011 The knowledge of individual families and subtypes of PDEs is considerable, but how the different PDEs collaborate in the cell to control a cAMP signal is still not fully understood. Cyclic AMP 139-143 phosphodiesterase 10A Homo sapiens 97-101 21931705-6 2011 Inhibition of membrane-bound or cytosolic PDEs can potentiate the cAMP response to adenylyl cyclase activation, but we see no significant difference between the potentiation of the cAMP response at the plasma membrane and in cytosol when membrane-bound and cytosolic PDEs are inhibited. Cyclic AMP 66-70 phosphodiesterase 10A Homo sapiens 42-46 18635550-1 2008 The tandem GAF domain of hPDE10A uses cAMP as an allosteric ligand (Gross-Langenhoff, M., Hofbauer, K., Weber, J., Schultz, A., and Schultz, J. E. (2006) J. Biol. Cyclic AMP 38-42 phosphodiesterase 10A Homo sapiens 25-32 21355834-2 2011 Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Cyclic AMP 114-118 phosphodiesterase 10A Homo sapiens 0-21 21355834-2 2011 Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Cyclic AMP 114-118 phosphodiesterase 10A Homo sapiens 23-29 21355834-2 2011 Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Cyclic AMP 220-224 phosphodiesterase 10A Homo sapiens 0-21 21355834-2 2011 Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Cyclic AMP 220-224 phosphodiesterase 10A Homo sapiens 23-29 21355834-3 2011 Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/PKA signalling in the basal ganglia, leading to the potentiation of dopamine D1 receptor signalling, and concomitant inhibition of dopamine D2 receptor signalling. Cyclic AMP 74-78 phosphodiesterase 10A Homo sapiens 46-52 20493887-1 2010 Cyclic nucleotide-specific phosphodiesterases (PDEs) play a critical role in signal transduction by regulating the level of adenosine 3",5"-cyclic monophosphate (cAMP) and guanosine 3",5"-cyclic monophosphate (cGMP) in cells. Cyclic AMP 124-160 phosphodiesterase 10A Homo sapiens 47-51 20493887-1 2010 Cyclic nucleotide-specific phosphodiesterases (PDEs) play a critical role in signal transduction by regulating the level of adenosine 3",5"-cyclic monophosphate (cAMP) and guanosine 3",5"-cyclic monophosphate (cGMP) in cells. Cyclic AMP 162-166 phosphodiesterase 10A Homo sapiens 47-51 20716858-2 2010 The effect of dopamine is largely mediated through the cAMP/PKA signaling cascade and therefore controlled by phosphodiesterases (PDEs). Cyclic AMP 55-59 phosphodiesterase 10A Homo sapiens 110-128 20716858-2 2010 The effect of dopamine is largely mediated through the cAMP/PKA signaling cascade and therefore controlled by phosphodiesterases (PDEs). Cyclic AMP 55-59 phosphodiesterase 10A Homo sapiens 130-134 19689430-5 2009 PDE10A and PDE11A are the two most recently described PDEs and it has been suggested that their GAF domains bind to cAMP and cGMP respectively. Cyclic AMP 116-120 phosphodiesterase 10A Homo sapiens 0-6 19689430-8 2009 The GAFb domain of PDE10A binds cAMP with a Kd of 48 nM and the GAFa domain of PDE11A binds cGMP with a Kd of 110 nM. Cyclic AMP 32-36 phosphodiesterase 10A Homo sapiens 19-25 17389385-1 2007 Phosphodiesterases (PDEs) hydrolyze the second messengers cAMP and cGMP. Cyclic AMP 58-62 phosphodiesterase 10A Homo sapiens 0-18 18477562-0 2008 Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. Cyclic AMP 98-102 phosphodiesterase 10A Homo sapiens 49-70 18477562-3 2008 PDE10A may be the only mammalian PDE for which cAMP is the GAF domain ligand, and it may be allosterically stimulated by cAMP. Cyclic AMP 47-51 phosphodiesterase 10A Homo sapiens 0-6 18477562-3 2008 PDE10A may be the only mammalian PDE for which cAMP is the GAF domain ligand, and it may be allosterically stimulated by cAMP. Cyclic AMP 121-125 phosphodiesterase 10A Homo sapiens 0-6 18477562-5 2008 Here we report the crystal structure of the C-terminal GAF domain (GAF-B) of human PDE10A complexed with cAMP at 2.1-angstroms resolution. Cyclic AMP 105-109 phosphodiesterase 10A Homo sapiens 83-89 18477562-9 2008 In the PDE10A GAF-B domain, cAMP tightly binds to a cNMP-binding pocket. Cyclic AMP 28-32 phosphodiesterase 10A Homo sapiens 7-13 17389385-1 2007 Phosphodiesterases (PDEs) hydrolyze the second messengers cAMP and cGMP. Cyclic AMP 58-62 phosphodiesterase 10A Homo sapiens 20-24 17389385-2 2007 It remains unknown how individual PDE families selectively recognize cAMP and cGMP. Cyclic AMP 69-73 phosphodiesterase 10A Homo sapiens 34-37 17389385-4 2007 The crystal structures of the catalytic domains of the D674A and D564N mutants of PDE10A2 in complex with cAMP and cGMP reveal that two substrates bind to the active site with the same syn configuration but different orientations and interactions. Cyclic AMP 106-110 phosphodiesterase 10A Homo sapiens 82-88 34735298-2 2021 PDE10A is able to hydrolyze both cAMP and cGMP. Cyclic AMP 33-37 phosphodiesterase 10A Homo sapiens 0-6 17263185-3 2007 Biochemical and behavioral studies indicate that the inhibition of PDE10A enhances striatal output by increasing activity in the cGMP and cAMP signaling pathways. Cyclic AMP 138-142 phosphodiesterase 10A Homo sapiens 67-73 10998054-1 2000 PDE10A is a cyclic nucleotide phosphodiesterase (PDE) exhibiting properties of a cAMP PDE and a cAMP-inhibited cGMP PDE. Cyclic AMP 81-85 phosphodiesterase 10A Homo sapiens 0-6 10998054-1 2000 PDE10A is a cyclic nucleotide phosphodiesterase (PDE) exhibiting properties of a cAMP PDE and a cAMP-inhibited cGMP PDE. Cyclic AMP 96-100 phosphodiesterase 10A Homo sapiens 0-6 15627479-10 2005 Expression of the following cAMP-PDE subtypes were detected by reverse transcriptase PCR (RT-PCR): PDE1A, PDE1C, PDE2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE10A and PDE11A. Cyclic AMP 28-32 phosphodiesterase 10A Homo sapiens 176-182 10441464-0 1999 Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Cyclic AMP 127-131 phosphodiesterase 10A Homo sapiens 93-110 10373451-0 1999 Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). Cyclic AMP 85-89 phosphodiesterase 10A Homo sapiens 100-106 10373451-3 1999 Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP. Cyclic AMP 71-75 phosphodiesterase 10A Homo sapiens 12-18 10373451-3 1999 Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP. Cyclic AMP 184-188 phosphodiesterase 10A Homo sapiens 12-18 10373451-6 1999 Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE. Cyclic AMP 39-43 phosphodiesterase 10A Homo sapiens 6-12 10373451-6 1999 Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE. Cyclic AMP 54-58 phosphodiesterase 10A Homo sapiens 6-12 34907481-2 2021 Phosphodiesterase (PDE) family members act in the degradation of cAMP and cGMP, among which some isoforms such as PDE9A are attracting interest for Alzheimer"s disease treatment, while PDE10A is used as target for treating schizophrenia. Cyclic AMP 65-69 phosphodiesterase 10A Homo sapiens 185-191 34671065-4 2021 cAMP is subsequently degraded by a set of phosphodiesterases (PDEs) which display cell-type specific expression and may also affect baseline levels of the messenger. Cyclic AMP 0-4 phosphodiesterase 10A Homo sapiens 42-60 34671065-4 2021 cAMP is subsequently degraded by a set of phosphodiesterases (PDEs) which display cell-type specific expression and may also affect baseline levels of the messenger. Cyclic AMP 0-4 phosphodiesterase 10A Homo sapiens 62-66 34671065-5 2021 To study which specific PDEs contribute most to cAMP regulation, we knocked down individual PDEs and recorded breakdown rates of cAMP levels following transient stimulation in HeLa cells stably expressing the FRET/FLIM sensor, Epac-SH189. Cyclic AMP 48-52 phosphodiesterase 10A Homo sapiens 92-96 34671065-8 2021 cAMP clearance was significantly slower when PDE3A and, to a lesser amount, PDE10A were knocked down, identifying these isoforms as dominant in HeLa cells. Cyclic AMP 0-4 phosphodiesterase 10A Homo sapiens 76-82